Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.2393
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jun 16, 26 |
Daily · Wilder smoothing
| Maxim Group |
| maintain |
| Buy |
| Buy |
| Mar 24, 26 | D. Boral Capital | maintain | Buy | Buy |
| Mar 24, 26 | Piper Sandler | maintain | Overweight | Overweight |
| Mar 24, 26 | Guggenheim | maintain | Buy | Buy |
| Nov 6, 25 | D. Boral Capital | maintain | Buy | Buy |
| Nov 6, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Oct 16, 25 | D. Boral Capital | maintain | Buy | Buy |
| Aug 7, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 7, 25 | D. Boral Capital | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 29.39 | Oscillator | Buy |
| Stochastic %K (14, 3, 3) | 11.99 | Oscillator | Buy |
| Williams %R (14) | -83.53 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.04 (Hist -0.00) | Oscillator | Strong Sell |
| Average Directional Index (14) | 44.21 (+DI 8.2 / -DI 26.8) | Trend | Strong Sell |
| EMA 20 | 0.28 | MA | Strong Sell |
| SMA 20 | 0.28 | MA | Strong Sell |
| EMA 50 | 0.40 | MA | Strong Sell |
| SMA 50 | 0.36 | MA | Strong Sell |
| SMA 200 | 1.49 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | CNTX | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -0.5x | -1.7x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -0.5x | EPS est. -0.46 | In line |
| Price / Book | 0.6x | 1.0x | Discount |
| Price / Sales | — | — | n/a |
| EV / EBITDA | 0.5x | 0.9x | Discount |
| Return on equity | -82.1% | — | Weak |
| Gross margin | 0.0% | 0.0% | n/a |
| Debt / Equity | 0.01 | 0.00 | Conservative |
| Piotroski / Altman Z | 2/9 | Z -5.35 | Distress |
Discounted cash flow model
Stock news · updated daily
CDZI, CNSY and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 15, 2026.
ATS, CANG and CNTX have been added to the Zacks Rank #5 (Strong Sell) List on October 13, 2026.
CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers PHILADELPHIA, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced that the first patient has been dosed in the Phase 1 clinical trial of CT-202, a Nectin-4 x CD3 TCE bispecific antibody.
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 2027 PHILADELPHIA, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, today announced its financial results for the second quarter ended June 30, 2026, and reported on recent and upcoming business highlights. “During the second quarter, we advanced our pipeline and reported interim Phase 1a data from CTIM-76 in a limited number of heavily pretreated patients with platinum-resistant ovarian cancer (“PROC”) receiving weekly dosing,” said Martin Lehr, Chief Executive Officer of Context.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | -0.09 | -0.15 | Miss -62.8% | — |
| May 6, 2026 | -0.12 | -0.09 | Beat 25.0% | — |
| Mar 19, 2026 | -0.11 | -0.14 | Miss -27.3% | — |
| Nov 5, 2025 | -0.09 | -0.10 | Miss -11.1% | — |
| Aug 6, 2025 | -0.06 | -0.09 | Miss -50.0% | — |
| May 7, 2025 | -0.05 | -0.05 | Beat 0.0% | — |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:03:50 | View |
| SC 13G/A | Aug 12, 2026 | 2026-08-12 16:30:24 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 16:16:31 | View |
| 10-Q | Aug 5, 2026 | 2026-08-05 16:09:43 | View |
| 8-K | Jul 31, 2026 | 2026-07-31 16:08:44 | View |
| SC 13G/A | Jul 31, 2026 | 2026-07-31 16:01:17 | View |
| SC 13G | Jul 27, 2026 | 2026-07-27 16:25:25 | View |
| 4 | Jun 26, 2026 | 2026-06-26 16:23:27 | View |
| 4 | Jun 26, 2026 | 2026-06-26 16:21:41 | View |
| 4 | Jun 26, 2026 | 2026-06-26 16:21:00 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 24, 26 | Pasternak Andy | director | A-Award | 45,000 @ $0.576 | $25.92K |
| Jun 24, 26 | Stacey Jennifer Evans | director | A-Award | 45,000 @ $0.576 | $25.92K |
| Jun 24, 26 | West Linda | director | A-Award | 45,000 @ $0.576 | $25.92K |
| Jun 24, 26 | Smith Karen L. | director | A-Award | 45,000 @ $0.576 | $25.92K |
| Jun 24, 26 | Walker Luke Nathaniel | director | A-Award | 45,000 @ $0.576 | $25.92K |
| Jun 24, 26 | Kantoff Philip W. | director | A-Award | 45,000 @ $0.576 | $25.92K |
| Feb 19, 26 | Levit Alex C. | officer: Chief Legal Officer, Corp. Sec | A-Award | 270,000 @ $2.32 | $626.4K |
| Feb 19, 26 | Minai-Azary Jennifer Lynn | officer: Chief Financial Officer | A-Award | 275,000 @ $2.32 | $638.0K |